Accuray Incorporated (0H8I.L)
| Previous close | 1.5350 |
| Open | 1.6950 |
| Bid | 0.0000 x N/A |
| Ask | 0.0000 x N/A |
| Day's range | 1.6893 - 1.7450 |
| 52-week range | 1.6893 - 4.2614 |
| Volume | |
| Avg. volume | 564 |
| Market cap | 1.645M |
| Beta (5Y monthly) | 1.47 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- PR Newswire
Accuray Reports Fiscal 2024 Third Quarter Financial Results
Accuray Incorporated (NASDAQ: ARAY) today reported financial results for the third quarter and nine-months ended March 31, 2024.
- PR Newswire
Accuray Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024
Accuray Incorporated (NASDAQ: ARAY) announced today that the company is showcasing advances in hardware and software designed to improve the cancer treatment experience, at ESTRO 2024. The latest generation CyberKnife® and Radixact® platforms provide medical care teams with the technology necessary for expanding the curative power of radiation therapy and delivering on the focus of this year's congress, bridging the care gap. The European Society for Radiotherapy and Oncology's (ESTRO) annual me
- PR Newswire
Accuray Expands Global Training Center Network With Opening of New Facility in Genolier, Switzerland
Accuray Incorporated (NASDAQ: ARAY) announced today that as part of its commitment to advancing patient care the company has opened a new training center in Genolier, Switzerland, that will serve as the European education hub for radiosurgery and radiotherapy product training, and sharing of best practices and innovative techniques using the latest model Accuray CyberKnife® and Radixact® Radiation Treatment Delivery Systems and Accuray Precision® Treatment Planning System. The Genolier based cen
